The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Potentially giving the liver a chance to rest and recover, Scottish scientists are working to perfect their artificial liver machine. Conceptually similar to kidney dialysis, this invention temporarily gives the liver a break from its constant duty of filtering out toxins.
Continue reading »Most people associate the removal of blood from their veins with donating to the Red Cross or getting tested for some ailment. However, the removal of blood from someone's body can serve many purposes. Learn how the safe ancient practice of bloodletting, or phlebotomy, has proven therapeutic value, and why it is gaining momentum as a treatment of chronic Hepatitis C.
Continue reading »While most cases of chronic viral hepatitis present a treatment challenge, treating the Hepatitis Delta virus is even harder. Soured by its high relapse rate, the only approved treatment for this infection is one year of interferon therapy. In their search for better solutions, Turkish researchers found that doubling the treatment length has no effect on this viral strain's response rates.
Continue reading »When you apply pressure to certain points on your body, it is possible to reduce pain and improve your health. Discover how acupressure can be used to relieve some common symptoms associated with Hepatitis C, including liver-area pain and fatigue.
Continue reading »Molecularly different than pegylated interferon, consensus interferon offers hope to non-responders. This retrospective study on U.S. veterans with Hepatitis C demonstrates that those with Hepatitis C RNA remaining after interferon-ribavirin therapy may have another option for future treatment.
Continue reading »OctoPlus has reported positive results from a Phase IIa trial for the Hepatitis C drug Locteron. Thus far, Locteron is encouraging due to its convenient dosing schedule, tolerability and Hepatitis C anti-viral activity.
Continue reading »Delivering encouraging news, pharmaceutical giant Roche shares results of two of its leading HCV drugs. As the result of a Phase IIa trial that combined Pegasys and Copegus with R1626, the Hepatitis C virus was undetectable in 81 percent of the study's participants. In collaboration with Pharmasset, a Phase I study of R7128 also demonstrated great promise against the virus.
Continue reading »Researchers have proven carbohydrates with a high glycemic index cause fat to accumulate in the liver. By stabilizing blood sugar levels, suggestions are given to reduce the risk high glycemic foods pose, thus minimizing the growing threat of fatty liver disease.
Continue reading »Although just a preliminary study, New York researchers have discovered a new use for a well-known diagnostic tool. Useful for evaluating more than just soft tissue injuries, this recent study supports MRI technology as an effective non-invasive method to replace or supplement liver biopsy.
Continue reading »Learn about the effect of alcohol on Hepatitis C, and whether or not its consumption, in any moderation, poses risks for people managing the virus.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
